Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®
April 25 2023 - 7:00AM
Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a
biotechnology company spanning multiple sectors, today announced
that Blue Water management will attend the American Urological
Association (“AUA”) Annual Meeting 2023 in Chicago, IL from April
28th to May 1st, 2023, to promote its asset ENTADFI®, an
FDA-approved treatment for benign prostatic hyperplasia (“BPH”).
Blue Water’s Chief Executive Officer, Joseph Hernandez, and
Senior Vice President of Marketing and Business Development, Frank
Jaeger, will be in attendance to discuss launch strategy for
ENTADFI® scheduled for later this year, as well as the benefits of
ENTADFI® versus traditional BPH therapies. Hernandez and Jaeger
will also be available to discuss the recent rebranding of Blue
Water, its transition into a commercial-stage biotechnology
company, and the infrastructure being developed to support sales of
ENTADFI®.
“This conference brings together the top urology leaders from
around the country, and we are thrilled to attend to promote
ENTADFI®,” said Hernandez. “We believe this product has the
potential to transform the BPH landscape and enhance the lives of
millions of men that suffer from BPH and associated erectile
dysfunction. We encourage all in attendance to visit our booth to
connect and learn about ENTADFI®, as we prepare for launch later
this year.”
BPH, a condition in men in which the prostate gland is enlarged
but not cancerous, is a common problem that affects the quality of
life in approximately half of men over the age of 50 and over 90%
of men over the age of 85. Men with BPH suffer from challenges with
urination flow, frequency, and urgency, and about 70% of men with
BPH also experience sexual dysfunction. In 2022, there were
approximately 44 million total prescriptions and 20 million new
prescriptions related to BPH symptoms. ENTADFI® is designed to
treat BPH and its associated symptoms. Over 55 million patients in
the United States have or are at risk for BPH.
Blue Water management will be available during the conference
for one-on-one meetings and can be found at booth 439. Interested
parties may request a one-on-one meeting at
investors@bluewatervaccines.com or contact Blue Water at (513)
620-4101.
About ENTADFI®
ENTADFI® is an oral, once daily treatment for benign prostatic
hyperplasia ("BPH") that combines finasteride, a 5α-reductase
inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor,
offering a more effective treatment option compared to other
available therapies. Clinical trials have shown that ENTADFI® is
more effective in treating BPH symptoms, including urinary
frequency, urgency, weak stream, and difficulty initiating or
maintaining urination, compared to finasteride monotherapy.
Additionally, ENTADFI® has demonstrated a favorable safety profile,
with fewer adverse sexual side effects compared to finasteride.
ENTADFI® reduces potential for adverse sexual side effects, making
it a preferred choice for men seeking relief from BPH symptoms
without compromising their sexual health. ENTADFI® has received FDA
approval for the indication of initiating treatment of the signs
and symptoms of BPH in men with an enlarged prostate for up to 26
weeks. More information about BPH and full ENTADFI® prescribing
information can be found on the product website at
https://entadfipatient.com/.
About Blue Water Biotech
Blue Water Biotech, Inc. is a biotechnology company focused on
developing transformational therapies to address significant health
challenges globally. Headquartered in Cincinnati, OH, the Company
holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children’s Hospital Medical
Center, St. Jude Children’s Hospital, and The University of Texas
Health Science Center at San Antonio. Blue Water is developing a
Streptococcus pneumoniae vaccine candidate, designed to
specifically prevent highly infectious middle ear infections, known
as acute otitis media (AOM), in children, and prevention of
pneumonia in the elderly. The Company is also developing a
universal flu vaccine that will provide protection from all
virulent strains in addition to licensing a novel norovirus (NoV)
S&P nanoparticle versatile virus-like particle (VLP) vaccine
platform from Cincinnati Children’s to develop vaccines for
multiple infectious diseases, including Marburg and monkeypox,
among others. Additionally, the Company is developing a Chlamydia
vaccine candidate with UT Health Science Center San Antonio to
prevent infection and reduce the need for antibiotic treatment
associated with contracting Chlamydia disease. Outside of its
vaccine franchise, Blue Water owns ENTADFI®, an FDA-approved, once
daily pill that combines finasteride and tadalafil for the
treatment of benign prostatic hyperplasia. This combination allows
men to receive treatment for their symptoms of BPH without the
negative sexual side effects typically seen in patients on
finasteride alone. For more information about Blue Water, visit
www.bluewatervaccines.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Blue Water’s current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to
Blue Water’s ability to realize the benefits of its acquisition of
ENTADFI®, risks related to BWV’s ability to expand its business
scope and its ability to commercialize ENTADFI®, risks related to
the development of Blue Water’s vaccine candidates; the failure to
obtain FDA clearances or approvals and noncompliance with FDA
regulations; delays and uncertainties caused by the global COVID-19
pandemic; risks related to the timing and progress of clinical
development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payor reimbursement;
limited research and development efforts and dependence upon third
parties; and substantial competition. As with any vaccine under
development, there are significant risks in the development,
regulatory approval and commercialization of new products. Blue
Water does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in Blue Water’s Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (the “SEC”) on March 9, 2023
and periodic reports filed with the SEC on or after the date
thereof. All of Blue Water’s forward-looking statements are
expressly qualified by all such risk factors and other cautionary
statements. The information set forth herein speaks only as of the
date thereof.
Media Contact Information:Blue Water Media
RelationsTelephone: (646) 942-5591 Email:
Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bluewatervaccines.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Oct 2023 to Oct 2024